Abstract
Phase II Study of Blinatumomab in Patients with B-Cell Lineage Acute Lymphocytic Leukemia with Positive Minimal/Measurable Residual Disease
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have